Spesolimab is a monoclonal antibody medication used to treat adults with moderate to severe plaque psoriasis. Spesolimab is a type of biologic therapy called an interleukin-17 (IL-17) inhibitor, which works by blocking IL-17, a protein that is overproduced in people with psoriasis. By blocking IL-17, spesolimab helps reduce the inflammation associated with psoriasis. Spesolimab is given as an intravenous (IV) infusion every four weeks for three doses. It is not a cure for psoriasis, but it can help reduce symptoms and improve quality of life for people with moderate to severe plaque psoriasis.
Spesolimab, sold under the brand name Spevigo, is a medication used for the treatment of generalized pustular psoriasis (GPP) flares in adults. It is a interleukin-36 receptor (IL-36R) antagonist, which means it works by blocking the action of interleukin-36, a protein that plays a role in inflammation. Spesolimab is given by injection into a vein.
Spesolimab was approved for medical use in the United States in September 2022. It was developed by Boehringer Ingelheim.